Drug Monitoring in Growth Hormone-Releasing Factor Therapy

Growth Hormone-Releasing Factor (GRF) therapy has emerged as a significant medical intervention for various conditions, primarily in the treatment of Growth Hormone Deficiency (GHD) in both children and adults. By stimulating the pituitary gland to release endogenous growth hormone (GH), GRF analogues like tesamorelin offer a more physiological approach compared to direct GH administration. While this therapy presents a promising alternative, ensuring its safety and efficacy requires meticulous drug monitoring. This page serves as a comprehensive resource for healthcare professionals, researchers, and patients on the essential aspects of drug monitoring in GRF therapy.